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Abstract Anti-neutrophil cytoplasmic autoantibodies recogniz-
ing conformational epitopes (c-ANCA) of proteinase 3 (PR3) 
from azurophil granules are a diagnostic hallmark in Wegener's 
granulomatosis (WG). Because a functional PR3 homologue has 
not been identified in rodents, it is difficult to assess 
immunopathological responses in rats or mice immunized with 
patients' derived c-ANCA or human PR3. Here we report the full 
length cDNA cloning and functional expression of murine PR3 in 
HMC-1 cells. Recombinant murine PR3 shows highly similar 
substrate specificities towards synthetic peptides and is inhibited 
by human al-proteinase inhibitor like human PR3. However, 
neither human c-ANCA, rabbit sera nor mouse monoclonal 
antibodies to human PR3 recognize the murine homologue. 
Consequently, it is unlikely that disease observed in mice after 
immunization with c-ANCA or human PR3 is caused by 
pathogenic antibodies directed against mouse PR3. Recombinant 
human-mouse chimaeric variants will be a valuable new tool to 
localize the disease-specific immunodominant epitopes in human 
PR3. 
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1. Introduction 
Autoantibodies specifically directed against conformational 
epitopes of PR3 (c-ANCA) are a disease-specific and pathog-
nomic feature of Wegener's granulomatosis (WG). Because 
disease activity and PR3-specific autoant ibody titers are 
highly correlated, autoantibodies are regarded as an impor-
tant pathogenic factor in this autoimmune disease [1-3]. How-
ever, direct evidence for the pathogenic role of c -ANCA is 
lacking, and pathogenic epitopes on conformationally intact 
human PR3 recognized by c-ANCA sera of W G patients have 
not been identified to date. To provide direct proof for anti-
body-dependent mechanisms of tissue damage and neutrophil 
activation, appropriate animal models are being sought by 
several investigators [4-6]. Recently, ANCA-like antibodies 
have been induced in mice by immunization with xenogeneic 
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A N C A from W G patients [7], but the interpretation of such 
model systems is conjectural in the absence of any knowledge 
about rodent PR3 homologues [8]. Indeed, observations that 
rabbit antibodies raised against purified human PR3 and hu-
man PR3-specific autoantibodies did not crossreact with ro-
dent neutrophils, were taken to indicate the absence of PR3 
homologues in rodents [3]. 
In the present study, we have identified and sequenced the 
murine PR3 c D N A and demonstrate that recombinant murine 
PR3 expressed in a human mast cell line shows highly similar 
functional properties toward synthetic substrates and inhibi-
tors as human P R 3 . Despite these strong similarities, autoan-
tibodies from 40 W G patients did not bind to natively folded 
murine PR3 indicating that the endogenous murine homo-
logue does not present any of those target epitopes which 
are required to study human ANCA-induced vasculitis in 
mice. 
2. Materials and methods 
2.1. Isolation of genomic clones for murine PR3 
A murine cosmid library prepared from the nuclear DNA of em-
bryonic stem cells (line cESI) in the vector pWE (a generous gift of S. 
Mudgett and R. Jaenisch) was screened using the human cDNA of 
PR3 previously cloned [9,10]. Partial sequences obtained for the third 
exon of the murine PR3 were used to design the gene specific primer 
DJ168 (5'-CACCCAGCACCACTGTCACAAG-3') annealing to the 
coding strand between position 254 and 274 (Fig. 1). The 5' sequence 
of the murine cDNA was completed by partially sequencing a ge-
nomic BamHI (located at position 38 within the first exon) -SacI 
fragment covering the promoter region and part of the first exon. 
2.2. Specific amplification of cDNA ends 
Messenger RNA of mouse and human bone marrow was isolated 
using a RNA isolation kit (Stratagene) and an oligo dT column (Phar-
macia). Poly A+ RNA was converted into adaptor-tagged double 
stranded cDNA using the Marathon cDNA amplification kit (Clon-
tech). The 5' end of the cDNA of PR3 was obtained by PCR with the 
common primer API (Clontech) and the oligonucleotide DJ168. The 
resulting PCR product was directly sequenced after gel purification. 
The 3' end of the cDNA was amplified using the two nested primers 
DJ186 (5'-CTC GGC CTT ATG TGG CAT CC-3', position 128 to 
147) derived from the 5' cDNA sequence and DJ127 (5'-TGG GTS 
HTG ACV GCB GCS CAY TGY-3', position 208 to 231, a degen-
erate primer coding for conserved amino-acid residues around the 
His-57 residue, Fig. 1) in combination with the adaptor primers 
API and AP2, respectively. The PCR products obtained were sub-
cloned into the vector pCRII (Invitrogen) and sequenced. 
2.3. Functional expression of murine and human PR3 in HMC-1 cells 
The full-length murine cDNA of PR3 was amplified from bone 
marrow cDNA using Pfui DNA polymerase (Amersham) and the 
primers DJ398, 5'-CCAGGTACCTGTCCATGGCTGGAAGCT (de-
rived from position 5 to 22) and DJ399, 5'-GCCATGCAT-
CACGTTTTGAATCCAGTC-3' (annealing between position 735 
and 752). The resulting PCR product was digested with Kpnl and 
Nsil and subcloned into a modified pcDNA3.1(+)Zeo vector (Invitro-
gen) in a way that a nucleotide sequence coding for two different tags 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 0 4 1 8 - 3 
188 
in tandem (MQHHHHHHHHSAWRHPQFGG, called His-Strep-
tag) was attached after the codon for residue 241 (bovine chymotryp-
sinogen A numbering, Fig. 1). 
The full-length human cDNA of PR3 was amplified by PCR from 
human bone marrow cDNA using the primers DJ376, 5'-
CCTGGATCCCACCATGGCTCAC-3 ' (nucleotide position - 1 3 to 
+9 relative to the translation start site containing an artificial BamHI 
site due to a C to T replacement at position —7) and DJ388, 5'-
CCAATGCATCGTAGAACGAATCCAGTC-3' (nucleotide position 
—48 to —31 relative to the stop codon followed by an artificial Nsil 
site containing sequence). The amplified cDNA fragment was direc-
tionally cloned into a BamHI and PstI site of a modified His-Strep-tag 
containing pcDNA3.1(+)Zeo vector. The His-Strep-tag was attached 
to the human and murine PR3 sequence at the same position after 
amino-acid residue 241. 
The human mast cell line HMC-1 was cultured and transfected as 
described [11]. To select PR3 expressing cell populations, HMC-1 cells 
were treated with Zeocin (Invitrogen) at a concentration of 100 ul/ml 
after 48 h. After selection, PR3-His-Strep-tag expressing cells were 
subjected to cloning by limiting dilution. 
2.4. Activity assays 
Proteolysis of synthetic substrates was performed as described [11], 
Five times 106 cells suspended in 20 mM Tris, 0.5 M NaCl, pH 7.5 
each were placed in microtiter wells, centrifuged at 900 X g, and fixed 
in 95% ethanol at 4°C for 5 min. Fixed cells were treated with 50 u.1 of 
1% Triton X-100 in 0.1 M Tris, pH 8.1 for 30 min at 37°C. Fifty ul of 
substrate solution (2 mM JV-methoxysuccinyl-Ala-Ala-Pro-Val-pNA 
or succinyl-Ala-Ala-Ala-pNA in 0.1 M Tris, pH 8.1) was added to 
the wells, and the hydrolysis of the substrate at 37°C was detected 
colorimetrically. Data are expressed as absorbance of p-nitroaniline at 
405 nm minus absorbance at 490 nm. For the inhibition experiments, 
detergent extracts of cells prepared as described [11] were transferred 
into fresh wells, and incubated with the inhibitors for 30 min at 37°C, 
prior to the addition of substrate. 
2.5. Antibodies and immunologie procedures 
The monoclonal antibodies (mABs) MCPR3-1 and MCPR3-2 were 
raised against human PR3 by immunization of mice with granule 
extracts from HMC-l/hPR3 cells (U. Specks, unpublished). 
MCPR3-1 and MCPR3-2 recognize PR3 from HMC-1 cells and hu-
man neutrophils in ELISAs and Western blots under nonreducing and 
reducing conditions. The mABs WGM2, 4A3, 5A3, 6A6, and the 
rabbit polyclonal anti-PR3 antibody were kindly provided by Dr. E. 
Csernok [12] and Dr. J. Wieslander [13]. C-ANCA positive sera with 
confirmed human PR3 reactivity were from patients with biopsy prov-
en WG [11]. Indirect immunofluorescence (IIF) on ethanol fixed cy-
tospin preparations of HMC-1/VEC, HMC-l/hPR3, HMC-l/hPR3-
tag, and HMC-l/mPR3-tag cells was performed as described [11]. 
3. Results and discussion 
3.1. The cDNA sequence and structure of murine PR3 
In the absence of irnmunological and biochemical evidence 
for the existence of a rodent homologue, PR3 has been con-
sidered as an elastase-related enzyme restricted to certain 
mammalian species including humans, primates and the horse 
[3,8,14]. Our attempts to find a crosshybridizing murine gene, 
however, were successful after screening a murine genomic 
library constructed from the DNA of embryonic stem cells. 
The nucleotide sequence of murine PR3 is 73%, the protein 
sequence 69% identical to the human sequences within the 
coding region of the mature enzyme (amino-acid residues 
from +16 to 243, bovine chymotrypsinogen A numbering ac-
cording to [17]) (see Fig. 1). Structural features common to 
catalytically active serine proteases are conserved including 
the His-57, Asp-102 and Ser-195 residues of the catalytic triad 
(square boxes in Fig. 1) and the eight cysteine residues 
(circled) which form intramolecular disulfide bonds. The sig-
nal peptide is two residues longer than in human PR3, the 
carboxy-terminal peptide tail is four residues shorter. Signal 
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peptidase most likely cleaves between alanine at position —3 
and serine at position —2 as predicted by computer programs 
(e.g. AnalyzeSignalase). The two residues Ser-Lys following 
this cleavage site represent a short propeptide in analogy to 
human PR3 [15,16]. The carboxy-terminal tetrapeptide Gly-
Ala-Glu-Pro of murine PR3 following position 243 is prob-
ably removed during biosynthesis. 
Since crystal structures have been solved for human PR3 
[17] and human neutrophil elastase (HNE) [18], sequence 
alignments with the murine PR3 (Fig. 1) permit us to suggest 
that substrate specificities and biological roles of the murine 
enzyme have not been changed significantly during mamma-
lian evolution. Residues that line the substrate binding pock-
ets SI to S3 [18] are pretty well conserved between the human 
and murine PR3, but differ from those of HNE [17,18]. Since 
He-190 of human and murine PR3 is replaced by a Val residue 
in HNE, HNE accepts larger aliphatic residues in its SI. The 
S2 pockets of murine and human PR3 have similar physico-
chemical properties, but are more polar than in HNE. 
3.2. Expression of enzymatically active recombinant mouse 
PR3 in HMC-1 cells 
HMC-1 cells were shown to have the appropriate process-
ing machinery that allows the biosynthesis and storage of 
enzymatically active and conformationally intact recombinant 
human PR3 in cytosolic granules. To demonstrate the func-
tional equivalence between the murine and the human gene 
products, we generated recombinant mouse PR3 and human 
PR3 with the same carboxy-terminal extension peptide 
(mPR3-tag and hPR3-tag) and compared their activities to 
human (untagged) PR3 [11]. HMC-1 cells transfected with 
the plasmids pcDNA3.1-Zeo/mPR3-tag and pcDNA3.1-Zeo/ 
hPR3-tag resulted in the cell lines HMC-l/mPR3-tag and 
HMC-1/hPR3-tag, respectively. HMC-1/HPR3 cells express-
ing wild type human PR3, HMC-1/PR3-S195A expressing 
an inactive mutant of PR3 and sham-transfected HMC-1/ 
VEC cells served as controls [11]. 
To address the question of correct processing, folding and 
conserved substrate specificity of murine PR3 in HMC-1 cells, 
the best tetra-peptide substrate known for human PR3, N-
methoxysuccinyl-Ala-Ala-Pro-Val-pNA (AAPV), was used to 
assess the catalytic activity of murine PR3. The hydrolysis of 
this substrate by lysates of HMC-l/mPR3-tag cells was equiv-
alent to that of HMC-l/hPR3-tag and HMC-1/HPR3 cells 
(Fig. 2A). No hydrolysis of this substrate was detected in 
parallel control experiments using lysates of HMC-1/PR3-
S195A or HMC-1 AVEC cells. Like the activity of wild type 
hPR3 and hPR3-tag, the activity of mPR3-tag for the same 
substrate was inhibited by greater than 95% in the presence of 
1.85 liM al-PI (Fig. 2B). No inhibition of recombinant PR3 
from either species was observed in the presence of 0.1 TIU/ 
ml aprotinin. In contrast, the activity of 2.5 ng of purified 
HNE, yielding the equivalent hydrolysis of AAPV in this as-
say, was inhibited by greater than 95% in the presence of 0.1 
TIU/ml aprotinin (Fig. 2B). Like wild type human PR3 and 
hPR3-tag, mPR3-tag did not hydrolyze the substrate succinyl-
Ala-Ala-Ala-pNA, which was cleaved by HNE in parallel 
control experiments (data not shown). Taken together, these 
results clearly support our conclusion that the serine protease 
homologue identified in the murine genome is not only the 
closest structural, but also the closest functional equivalent for 
human PR3 in the mouse species. Moreover, our functional 
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Fig. 1. Nucleotide sequence of murine PR3 and alignment of the cDNA-derived amino-acid sequence to that of human PR3. The nucleotide se-
quence numbering starts with the first base shown. Periods are put at every tenth position. Amino-acid residues are shown by standard one-let-
ter symbols below the first base of the respective codon. The third row shows the amino-acid residues of human PR3 which disagree with the 
murine sequence, identical residues are marked by - . Protein sequences are numbered on the basis of tertiary structure similarities to bovine 
chymotrypsinogen A like in [17]. The residues His-57, Asp-102 and Ser-195 that form the catalytic triad, are boxed, cysteine residues are circled 
and 7V-glycosylation sites are highlighted by black squares. The polyadenylation signal AATAAA in the 3' untranslated region has been under-
lined. The vertical solid arrows indicate the predicted sites of amino- and carboxy-terminal biosynthetic processing, the dashed vertical arrow 
the most likely site of cleavage by signal peptidase. 
studies demonstrate that HMC-1 cells also have the capacity 
to correctly process the murine propeptide which requires 
cleavage after a lysine instead of cleavage after a glutamate 
residue. 
3.3. Antigenic sites differ between human and murine PR3 
Antigenicity of hPR3, hPR3-tag and mPR3-tag was studied 
by IIF using the mABs WGM2, 4A5, 5A6, 6A6, MCPR3-1 
and MCPR3-2 as well as a rabbit polyclonal anti-PR3 serum 
that had been generated by immunization with native human 
PR3 [13]. None of these antibodies detected mouse PR3 in 
HMC-1/mPR3-tag cells. By assessing reactivity of antibodies 
toward mPR3-tag expressing HMC-1 cells we circumvented 
the problem of antigen-independent binding of immunoglobu-
lins to mouse neutrophils. Our results clearly show that the 
antigenic determinants of native human PR3 that are recog-
nized by rabbit as well as mouse monoclonal antibodies, are 
not preserved on mouse PR3. This probably explains why the 
existence of mouse PR3 has been elusive to date. 
3.4. ANC A lack specificity for murine PR3 
To evaluate the feasibility of vasculitis induction in mice by 
passive transfer of c-ANCA, active idiotypic immunization 
with c-ANCA [7] or immunization with human PR3, we ad-
dressed the question whether human c-ANCA have the prop-
erties to directly bind to murine PR3. Even the concept of 
disease induction by idiotypic immunization implies that the 
finally emerging anti-idiotype antibodies against c-ANCA-spe-
cific murine antibodies recognize both the human PR3 as well 
as the murine homologue. In previous studies the binding of 
murine antibodies to human PR3 from immunized mice had 
been substantiated [7,19], but the reactivity of murine anti-
idiotype antibodies toward murine neutrophils remained spec-
ulative. 
Forty c-ANCA positive unselected serum samples with high 
titers (median 1:256, range 1:128 to 1:1024), as determined by 
standard IIF using neutrophil cytospin preparations, were, 
therefore, evaluated in parallel on HMC-l/hPR3, HMC-1/ 
hPR3-tag, and HMC-1/mPR3-tag cells by IIF at serum dilu-
tions of 1:20. All 40 sera reacted with both human PR3 var-
iants, but none reacted with mouse PR3-tag expressing cells. 
These data indicate that the epitopes of human PR3 recog-
nized by human autoantibodies are not preserved on mouse 
PR3. Since all sera recognized the human wild type PR3 as 
well as the human PR3-tag-modified protein, we are able to 
rule out that the His-Strep-tag has changed the tertiary struc-
ture of murine PR3 to a degree that would disturb its binding 
to c-ANCA. Since eel-PI binding and recognition of identical 
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The presence of a tag at the carboxy-terminus of human 
and murine PR3 obviously does not affect their enzymatic 
activities toward specific synthetic substrates, their inhibition 
by large molecular weight inhibitors like oil-PI, and the anti-
genicity of human PR3 toward c-ANCA which is conforma-
tion sensitive. Carboxy-terminally tagged PR3 molecules are 
sorted and stored in granules of HMC-1 cells like wild type 
PR3 (data not shown) and do not interfere with the subcel-
lular routing of granule-associated serine proteases. Our ob-
servations are consistent with results from previous studies 
showing that deletion variants of HNE and cathepsin G lack-
ing the carboxy-terminal propeptides have identical catalytic 
activities and are efficiently targeted to granules [20]. Adding a 
versatile peptide tag at the carboxy-terminus with affinities for 
protein ligands (streptavidin) and Ni-NTA matrices should 
facilitate the immunological characterization of c-ANCA epi-
topes using purified human-mouse chimaeric PR3 variants in 
the future. 
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Fig. 2. Enzymatic activity of recombinant mouse PR3. (A) Hydroly-
sis of the substrate ./V-methoxysuccmyl-Ala-Ala-Pro-Val-pNA by 
HMC-l/mPR3-tag (full squares), HMC-l/hPR3-tag (open squares), 
and HMC-l/hPR3 cells (open circles) was equivalent. No hydrolysis 
of this substrate was observed with lysates of HMC-1/PR3-S195A 
(triangles) or HMC-1/VEC cells (inverted triangles). (B) Hydrolysis 
of this substrate by tagged mouse and human PR3 as well as wild 
type human PR3 was inhibited by greater than 95% by 1.85 uM 
cel-PI (black bars), but not by 0.1 TIU/ml aprotinin (grey bars). 
HNE served as control in these experiments. Each data point repre-
sents the mean of triplicates. Shown are representative examples of 
five (A) and four (B) different experiments. 
tetrapeptide substrates implies a certain degree of surface con-
servation between the murine and human PR3, the absence of 
cross-reactivity of c-ANCA with murine PR3 is rather surpris-
ing. These data suggest that the passive transfer of human 
c-ANCA and the idiotypic immunization of mice with human 
c-ANCA resulting in a murine vasculitis [7,19] do not provide 
an animal model that allows the unequivocal clarification of 
the pathogenicity of WG-specific autoantibodies. 
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